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Patient Perspectives on Medication Assisted Therapy in Vermont
Ashley Adkins, Holly Bachilas, Florence DiBiase, Michael Marallo, John Paul Nsubuga, Lloyd Patashnick, Curran Uppaluri,
Elizabeth Cote, Charles MacLean MD, Jan Carney MD MPH
The Robert Larner, MD College of Medicine at the University of Vermont, Burlington, VT

BACKGROUND
• Medication-Assisted Therapy (MAT) for opioid addiction
has increased in Vermont over the past 10 years,
supported by a novel “Hub and Spoke” system that
integrates specialty treatment centers (“Hubs”) with
primary care offices (“Spokes”). 1
• Vermont has the highest per capita use of buprenorphinebased MAT in the US.1
• Barriers to successful MAT include: transportation,
stigma, waiting time, insurance coverage, and others.2
• Studies of patient perspectives of MAT have identified
social barriers (interference of treatment with work,
school, or life obligations); rigid program rules; concerns
about withdrawal and relapse as common causes of
premature discontinuation of treatment.3
• In contrast, patients have reported a high-level of
satisfaction with primary care office-based MAT.4

RESULTS
N=44
34 (21-61)

Table. Patient Characteristics
Age, median (range)

72%

Sex, % female
Education
Less than high school diploma
High school diploma
Some college or greater

23%
43%
34%

Duration in treatment, median (range)

42 mo (2 wks - 25 yrs)
52%

Multiple treatment attempts, %
Time on waitlist, median
Non-pregnant
Pregnant

11 mo
0 mo

Dependent children, %

41%

Comorbidities
• 22/44 (50%) of patients cited a comorbid mental health conditions,
most commonly depression, anxiety, ADD/ADHD, PTSD
• 9/44 (20%) cited chronic pain
• 5/44 (11%) cited a physical disability or musculoskeletal injury

DISCUSSION

4. System
Having a highly functioning treatment system and good
social supports were important enablers of success
• 31/44 (70%) felt they understood the MAT system, though
navigating the system was difficult when initiating treatment
• 30/44 (68%) had no issues with clinician availability
• 10/44 (23%) reported some negative experiences

• Patients reported confidence in the Hub and Spoke system and
high levels of self-efficacy.

5. Social Support & Stigma

• In this sample, patients felt well-supported by family, friends and
the treatment system, but feelings of stigma remain.

• 36/44 (82%) felt well-supported to prevent relapse
• 23/44 (52%) felt they were supported by healthcare
professionals
• 16/44 (36%) did not feel supported by healthcare
professionals, feeling disrespected at times (both at MAT
centers and other settings such as the Emergency
Department)
• 18/44 (41%) highlighted at least one source of stigma

"Depends on the person. Sometimes they treat you like
a dirt bag. Sometimes they respect you“

6. Self-Efficacy

Project goal
To elicit patient perspectives on barriers and
enablers of successful MAT in Chittenden County,
Vermont

2. Housing
• 27/44 (61%) have permanent housing, of which 7/44 (16%) are in
section 8 housing
• 15/44 (34%) are transitory or live with relatives

3. Employment

• Guided interviews of 44 patients enrolled in MAT for opioid
addiction at the 2 hubs of the Chittenden Clinic in
Burlington, VT were conducted in October 2016.
• Questionnaire items were developed based on previous
literature and discussion with program leadership, staff and
clinicians and community stakeholders.
• Responses were organized using thematic content analysis
with consensus across seven interviewers and two
analysts.
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• Compare patient and provider perspectives to further
inform system improvement and allocate resources
effectively.
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Does this program give you the tools to succeed?
Do you feel you have the power to overcome your opioid addiction?

10

7%

• 26/44 (59%) defined success as staying sober
• 12/44 (27%) defined success with feeling a sense of
independence

5%

Do Not Work
16%
54%
18%

Work <30 hrs

8. Motivators

Work >30 hrs

• 12/44 (27%) identified family as a major motivator
• 12/44 (27%) reported that being healthy, free from numerous
hospitalizations was a motivator to continue treatment

No Response
Volunteer

• Develop a quantitative questionnaire for deployment
across the statewide MAT system.

10= Most Confident

7. Success

METHODS

• Some interactions with health providers were perceived as
disrespectful and dismissive of pain complaints. Understanding
health care provider and patient perspectives in these situations
has the potential to suggest solutions.

• Assess and understand common comorbid conditions
and how they affect success in the program.

Confidence in the System and Self-Efficacy
Number of Respondents

• 11/44 (25%) reported access issues, most commonly transportation
or time commitment

• Sobriety, family support and developing independence motivated
patients to succeed in the program.

FUTURE DIRECTIONS

Patient Perspectives
Access, housing and financial problems were important
barriers to successful treatment
1. Access

• Patients in MAT have complex medical, mental health, social,
personal, and work lives, all of which need attention to maximize
treatment success.

• Explore better ways to integrate social support services
with substance abuse programs to create a unified
system.
• Offer provider education on effective approaches to
meet the needs of patients.
• Work to reduce stigma and increase empathy among
both providers and communities.
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“Sober Housing is crucial”
“It is easier to stay clean with good finances”

“My loved ones”
“Getting a good job and having a better life”

